Y-Biologics (XKRX:338840) Accounts Payable & Accrued Expense : ₩590 Mil (As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Y-Biologics Accounts Payable & Accrued Expense?

Y-Biologics's quarterly accounts payable & accrued expense declined from Sep. 2023 (₩598 Mil) to Dec. 2023 (₩263 Mil) but then increased from Dec. 2023 (₩263 Mil) to Mar. 2024 (₩590 Mil).

Y-Biologics's annual accounts payable & accrued expense increased from Dec. 2020 (₩383 Mil) to Dec. 2021 (₩552 Mil) and increased from Dec. 2021 (₩552 Mil) to Dec. 2022 (₩653 Mil).

Y-Biologics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Y-Biologics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Y-Biologics Accounts Payable & Accrued Expense Chart

Y-Biologics Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

501.84

506.78

382.73

551.91

652.98

Y-Biologics Quarterly Data
	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial				881.47	517.73	598.35	263.18	590.09

Y-Biologics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Y-Biologics (XKRX:338840) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Y-Biologics Inc (XKRX:338840) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 715, 17, Tech-ro 4-ro, Yuseong-gu, Daejeon, KOR

Website

https://www.ybiologics.com

Y-Biologics Inc is a company has a variety of development candidate antibodies based on Korea's highest-level antibody discovery platform technology and then independently develops antibody treatments or jointly develops cutting-edge biopharmaceuticals by fusing them with our partner's platform technology. Its main business model is based on a globally competitive antibody discovery platform and consists of development of new bio drug candidates and early technology transfer, and contract research services that generate stable cash flow.

Y-Biologics (XKRX:338840) Headlines

No Headlines